Shots:

• 23andMe has out-license its bispecific mAb targeted to block three members of the IL-36 cytokine subfamily & will leverage Almirall’s expertise in medical dermatology & accelerating the development the preclinical program
• Almirall to get exclusive WW rights to develop and commercialize the mAbs and will also be responsible for clinical studies. The focus of the agreement is to strengthen ALmirall’s early-stage research portfolio
• IL-36 is an IL-1 cytokine family targeted for associated with multiple inflammatory diseases- including various dermatological conditions

Click here to read full press release/ article | Ref: Almirall | Image: Twitter